BPG is committed to discovery and dissemination of knowledge
Cited by in F6Publishing
For: Kuo CH, Kuo FC, Hu HM, Liu CJ, Wang SS, Chen YH, Hsieh MC, Hou MF, Wu DC. The Optimal First-Line Therapy of Helicobacter pylori Infection in Year 2012. Gastroenterol Res Pract 2012;2012:168361. [PMID: 22792095 DOI: 10.1155/2012/168361] [Cited by in Crossref: 22] [Cited by in F6Publishing: 26] [Article Influence: 2.2] [Reference Citation Analysis]
Number Citing Articles
1 Ozturk O, Doganay L, Colak Y, Yilmaz Enc F, Ulasoglu C, Ozdil K, Tuncer I. Therapeutic success with bismuth-containing sequential and quadruple regimens in Helicobacter pylori eradication. Arab Journal of Gastroenterology 2017;18:62-7. [DOI: 10.1016/j.ajg.2017.05.002] [Cited by in Crossref: 8] [Cited by in F6Publishing: 6] [Article Influence: 1.6] [Reference Citation Analysis]
2 Song Y, Dou F, Zhou Z, Yang N, Zhong J, Pan J, Liu Q, Zhang J, Wang S. Microarray-Based Detection and Clinical Evaluation for Helicobacter pylori Resistance to Clarithromycin or Levofloxacin and the Genotype of CYP2C19 in 1083 Patients. Biomed Res Int 2018;2018:2684836. [PMID: 30276203 DOI: 10.1155/2018/2684836] [Cited by in Crossref: 6] [Cited by in F6Publishing: 6] [Article Influence: 1.5] [Reference Citation Analysis]
3 Dong SQ, Singh TP, Wei X, Yao H, Wang HL. Review: A Japanese population-based meta-analysis of vonoprazan versus PPI for Helicobacter pylori eradication therapy: Is superiority an illusion? Helicobacter 2017;22:e12438. [DOI: 10.1111/hel.12438] [Cited by in Crossref: 27] [Cited by in F6Publishing: 24] [Article Influence: 5.4] [Reference Citation Analysis]
4 Miftahussurur M, Yamaoka Y. Appropriate first-line regimens to combat Helicobacter pylori antibiotic resistance: an Asian perspective. Molecules. 2015;20:6068-6092. [PMID: 25856059 DOI: 10.3390/molecules20046068] [Cited by in Crossref: 20] [Cited by in F6Publishing: 20] [Article Influence: 2.9] [Reference Citation Analysis]
5 Lahbabi M, Alaoui S, El Rhazi K, El Abkari M, Nejjari C, Amarti A, Bennani B, Mahmoud M, Ibrahimi A, Benajah DA. Sequential therapy versus standard triple-drug therapy for Helicobacter pylori eradication: Result of the HPFEZ randomised study. Clin Res Hepatol Gastroenterol. 2013;37:416-421. [PMID: 23168228 DOI: 10.1016/j.clinre.2012.10.002] [Cited by in Crossref: 14] [Cited by in F6Publishing: 14] [Article Influence: 1.4] [Reference Citation Analysis]
6 Hassan AM, Shawky MAE, Mohammed AQ, Haridy MA, Eid KA. Simvastatin improves the eradication rate of Helicobacter pylori: upper Egypt experience. Infect Drug Resist 2019;12:1529-34. [PMID: 31239728 DOI: 10.2147/IDR.S202346] [Cited by in Crossref: 4] [Cited by in F6Publishing: 2] [Article Influence: 1.3] [Reference Citation Analysis]
7 Kuo CH, Lu CY, Shih HY, Liu CJ, Wu MC, Hu HM, Hsu WH, Yu FJ, Wu DC, Kuo FC. CYP2C19 polymorphism influences Helicobacter pylori eradication. World J Gastroenterol 2014; 20(43): 16029-16036 [PMID: 25473155 DOI: 10.3748/wjg.v20.i43.16029] [Cited by in CrossRef: 48] [Cited by in F6Publishing: 42] [Article Influence: 6.0] [Reference Citation Analysis]
8 Ciccaglione AF, Tavani R, Grossi L, Cellini L, Manzoli L, Marzio L. Rifabutin Containing Triple Therapy and Rifabutin with Bismuth Containing Quadruple Therapy for Third-Line Treatment of Helicobacter pylori Infection: Two Pilot Studies. Helicobacter 2016;21:375-81. [PMID: 26807668 DOI: 10.1111/hel.12296] [Cited by in Crossref: 18] [Cited by in F6Publishing: 17] [Article Influence: 3.0] [Reference Citation Analysis]
9 Liao XM, Nong GH, Chen MZ, Huang XP, Cong YY, Huang YY, Wu BH, Wei JQ. Modified sequential therapy vs quadruple therapy as initial therapy in patients with Helicobacter infection. World J Gastroenterol 2015; 21(20): 6310-6316 [PMID: 26034367 DOI: 10.3748/wjg.v21.i20.6310] [Cited by in CrossRef: 4] [Cited by in F6Publishing: 5] [Article Influence: 0.6] [Reference Citation Analysis]
10 Ciccaglione AF, Cellini L, Grossi L, Manzoli L, Marzio L. A Triple and Quadruple Therapy with Doxycycline and Bismuth for First-Line Treatment of Helicobacter pylori Infection: A Pilot Study. Helicobacter. 2015;20:390-396. [PMID: 25801708 DOI: 10.1111/hel.12209] [Cited by in Crossref: 16] [Cited by in F6Publishing: 14] [Article Influence: 2.3] [Reference Citation Analysis]
11 Zullo A, Scaccianoce G, De Francesco V, Ruggiero V, D’Ambrosio P, Castorani L, Bonfrate L, Vannella L, Hassan C, Portincasa P. Concomitant, sequential, and hybrid therapy for H. pylori eradication: a pilot study. Clin Res Hepatol Gastroenterol. 2013;37:647-650. [PMID: 23747131 DOI: 10.1016/j.clinre.2013.04.003] [Cited by in Crossref: 59] [Cited by in F6Publishing: 60] [Article Influence: 6.6] [Reference Citation Analysis]
12 Wang Y, Zhao R, Wang B, Zhao Q, Li Z, Zhu-ge L, Yin W, Xie Y. Sequential versus concomitant therapy for treatment of Helicobacter pylori infection: an updated systematic review and meta-analysis. Eur J Clin Pharmacol 2018;74:1-13. [DOI: 10.1007/s00228-017-2347-7] [Cited by in Crossref: 14] [Cited by in F6Publishing: 12] [Article Influence: 2.8] [Reference Citation Analysis]
13 Wu Z, Hou J, Wang Y, Chai M, Xiong Y, Lu W, Pan J. Preparation and evaluation of amoxicillin loaded dual molecularly imprinted nanoparticles for anti- Helicobacter pylori therapy. International Journal of Pharmaceutics 2015;496:1006-14. [DOI: 10.1016/j.ijpharm.2015.10.065] [Cited by in Crossref: 11] [Cited by in F6Publishing: 7] [Article Influence: 1.6] [Reference Citation Analysis]
14 Ciccaglione AF, Cellini L, Grossi L, Marzio L. Quadruple therapy with moxifloxacin and bismuth for first-line treatment of Helicobacter pyloriWorld J Gastroenterol 2012; 18(32): 4386-4390 [PMID: 22969203 DOI: 10.3748/wjg.v18.i32.4386] [Cited by in CrossRef: 13] [Cited by in F6Publishing: 16] [Article Influence: 1.3] [Reference Citation Analysis]
15 Mansour-Ghanaei F, Samadi A, Joukar F, Tirgar Fakheri H, Hassanipour S, Ashoobi MT, Soltanipour S, Alizadeh A, Rezamand G, Fathalipour M. Efficacy and tolerability of fourteen-day sequential quadruple regimen: pantoprazole, bismuth, amoxicillin, metronidazole and or furazolidone as first-line therapy for eradication of Helicobacter pylori: a randomized, double-blind clinical trial. EXCLI J 2019;18:644-52. [PMID: 31611747 DOI: 10.17179/excli2019-1613] [Cited by in F6Publishing: 1] [Reference Citation Analysis]
16 Zhao S, Lv Y, Zhang JB, Wang B, Lv GJ, Ma XJ. Gastroretentive drug delivery systems for the treatment of Helicobacter pyloriWorld J Gastroenterol 2014; 20(28): 9321-9329 [PMID: 25071326 DOI: 10.3748/wjg.v20.i28.9321] [Cited by in F6Publishing: 2] [Reference Citation Analysis]
17 Yang Y, Ouyang R, Xu L, Guo N, Li W, Feng K, Ouyang L, Yang Z, Zhou S, Miao Y. Review: Bismuth complexes: synthesis and applications in biomedicine. Journal of Coordination Chemistry 2015;68:379-97. [DOI: 10.1080/00958972.2014.999672] [Cited by in Crossref: 70] [Cited by in F6Publishing: 33] [Article Influence: 10.0] [Reference Citation Analysis]
18 Nahm JH, Kim WK, Kwon Y, Kim H. Detection of Helicobacter pylori with clarithromycin resistance-associated mutations using peptide nucleic acid probe-based melting point analysis. Helicobacter 2019;24:e12634. [PMID: 31304664 DOI: 10.1111/hel.12634] [Cited by in Crossref: 3] [Cited by in F6Publishing: 3] [Article Influence: 1.0] [Reference Citation Analysis]
19 Zhang J, Zhong J, Ding J, Shi J, Tang T, Liu Q, Huang H, Dai L, Yang N. Simultaneous detection of human CYP2C19 polymorphisms and antibiotic resistance of Helicobacter pylori using a personalised diagnosis kit. J Glob Antimicrob Resist 2018;13:174-9. [PMID: 29444465 DOI: 10.1016/j.jgar.2017.12.018] [Cited by in Crossref: 1] [Cited by in F6Publishing: 2] [Article Influence: 0.3] [Reference Citation Analysis]
20 Nijevitch AA, Idrisov B, Akhmadeeva EN, Graham DY. Choosing optimal first-line Helicobacter pylori therapy: a view from a region with high rates of antibiotic resistance. Curr Pharm Des 2014;20:4510-6. [PMID: 24180406 DOI: 10.2174/13816128113196660728] [Cited by in Crossref: 5] [Cited by in F6Publishing: 6] [Article Influence: 0.7] [Reference Citation Analysis]
21 Camargo MC, García A, Riquelme A, Otero W, Camargo CA, Hernandez-García T, Candia R, Bruce MG, Rabkin CS. The problem of Helicobacter pylori resistance to antibiotics: a systematic review in Latin America. Am J Gastroenterol. 2014;109:485-495. [PMID: 24589670 DOI: 10.1038/ajg.2014.24] [Cited by in Crossref: 95] [Cited by in F6Publishing: 80] [Article Influence: 11.9] [Reference Citation Analysis]
22 Almeida N, Romãozinho JM, Donato MM, Luxo C, Cardoso O, Cipriano MA, Marinho C, Sofia C. Triple therapy with high-dose proton-pump inhibitor, amoxicillin, and doxycycline is useless for Helicobacter pylori eradication: a proof-of-concept study. Helicobacter 2014;19:90-7. [PMID: 24506175 DOI: 10.1111/hel.12106] [Cited by in Crossref: 17] [Cited by in F6Publishing: 15] [Article Influence: 2.1] [Reference Citation Analysis]
23 Wu TS, Hu HM, Kuo FC, Kuo CH. Eradication of Helicobacter pylori infection. Kaohsiung J Med Sci. 2014;30:167-172. [PMID: 24656156 DOI: 10.1016/j.kjms.2013.11.003] [Cited by in Crossref: 13] [Cited by in F6Publishing: 15] [Article Influence: 1.4] [Reference Citation Analysis]
24 Mansour-Ghanaei F, Joukar F, Naghipour MR, Forouhari A, Seyed Saadat SM. Seven-day quintuple regimen as a rescue therapy for Helicobacter pylori eradication. World J Gastroenterol 2015; 21(2): 661-666 [PMID: 25593496 DOI: 10.3748/wjg.v21.i2.661] [Cited by in CrossRef: 14] [Cited by in F6Publishing: 10] [Article Influence: 2.0] [Reference Citation Analysis]
25 Tai WC, Liang CM, Lee CH, Chiu CH, Hu ML, Lu LS, Kuo YH, Kuo CM, Yen YH, Kuo CH. Seven-Day Nonbismuth Containing Quadruple Therapy Could Achieve a Grade “A” Success Rate for First-Line Helicobacter pylori Eradication. Biomed Res Int. 2015;2015:623732. [PMID: 26090428 DOI: 10.1155/2015/623732] [Cited by in Crossref: 16] [Cited by in F6Publishing: 15] [Article Influence: 2.3] [Reference Citation Analysis]
26 Jung SM, Cheung DY, Kim JI, Kim I, Seong H. Comparing the Efficacy of Concomitant Therapy with Sequential Therapy as the First-Line Therapy of Helicobacter pylori Eradication. Gastroenterol Res Pract 2016;2016:1293649. [PMID: 26823662 DOI: 10.1155/2016/1293649] [Cited by in Crossref: 8] [Cited by in F6Publishing: 7] [Article Influence: 1.1] [Reference Citation Analysis]